Sai Life Sciences Ltd Share Price

Sai Life Sciences Limited was originally incorporated as Sai Dru Syn Laboratories Limited as a Public Limited Company dated January 25 1999 issued by the Registrar of Companies Andhra Pradesh at Hyderabad. The Company received the Certificate of Commencement of Business from Registrar of Companies Andhra Pradesh on February 17 1999. Subsequently the Company name was changed from Sai Dru Syn Laboratories Limited to Sai Life Sciences Limited dated December 16 2003.Thereafter the name of the Company was changed from Sai Life Sciences Limited to Sai Advantium Pharma Limited dated August 30 2006 issued by the Registrar of Companies Andhra Pradesh. Subsequently the Company name was changed from Sai Advantium Pharma Limited to Sai Life Sciences Limited and a fresh Certificate of Incorporation dated May 28 2012 was issued by the Registrar of Companies Andhra Pradesh at Hyderabad.The Company is an innovatorfocused contract research development and manufacturing organization CRDMO. The Company provide endtoend services across the drug discovery development and manufacturing value chain for small molecule NCE to global pharmaceutical innovators companies and biotechnology firms. It possess both a discovery / contract research and b CMC / CDMO capabilities.Through the Scheme of Amalgamation Prasad Drugs Limited was merged into the Company in 2004. The Company acquired Merrifield Pharma Private Limited in 2006. Later the Company opened new areas of biology facility in Watertown Greater Boston MA U.S.A. for innovative and creative smallmolecule drugs in 2019. It launched Sai Nxt an initiative to transform the organization into a new generation CDMO in 2020. It further added cellular analysis platforms at its discovery biology facility in Cambridge Massachusetts USA.In 2021 the Company opened a new discovery biology facility at Unit II Plant in Hyderabad. In 2022 it opened the first set of new disconvery chemistry labs at Unit III Plant Hyderabad. In 2023 the Company opened high potency API manufacturing block at Unit IV Bidar Facility and has started API developability formulations DF capabilities at Unit II Hyderabad in 2024.The Company is proposing to raise money from public through IPO by issue and allotment of 61573120 Equity Shares through Offer for Sale and a Fresh Issue aggregating to Rs 800 Crores Equity Shares..

Revenue: ₹537.47Cr as on September 2025 (Q2 FY26)
Net Profit: ₹83.84Cr as on September 2025 (Q2 FY26)
Listing date: 18 Dec, 2024
Chairperson Name: Ranga Raju Kanumuri